

Special Issue

Bacteriocins—Potential Clinical Antimicrobials

Message from the Guest Editor

The world is facing a significant increase in infections caused by drug-resistant agents. In this scenario, bacteriocins fit as a promising and interesting alternative to conventional antibiotics in medical applications as potential antimicrobials and as possible immune-modulating agents. Although its potential as a food preservative is well explored, insufficient data on safety, toxicity, and clinical application represent a barrier to developing new therapeutic strategies. This Special Issue will collect original research, reviews, mini-reviews, perspectives, and opinion articles on the clinical application of bacteriocins. The proposal intends to bring together works that add knowledge to a better understanding of the bacteriocins as clinical antimicrobials and, in turn, contribute to developing more efficient strategies for combating infectious bacteria. Keywords: New antimicrobials; Antimicrobial peptides; Bioactive agents; Bacteriocins toxicity; Mechanism of action; Antibacterial activity; Drug tolerance

Guest Editor

Prof. Dr. Maria Cristina Dantas Vanetti

Department of Microbiology, Federal University of Viçosa (UFV), Viçosa, Brazil

Deadline for manuscript submissions

closed (30 April 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/95520

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)